European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

Description du projet

La banque de cellules souches éthiques d’Europe élargit de manière exponentielle son utilité et sa portée

La recherche sur les cellules souches est extrêmement prometteuse, mais a toujours soulevé des problèmes éthiques relatifs aux aspects moraux de l’utilisation d’embryons humains. Au cours de la dernière décennie, une découverte surprenante a évolué jusqu’à modifier le visage de la recherche sur les cellules souches. Les cellules souches pluripotentes induites (CSPI) sont des cellules somatiques humaines adultes, généralement des cellules de la peau ou du sang, génétiquement reprogrammées à un état semblable à celui des cellules souches embryonnaires. L’Europe dispose désormais d’une banque de CSPI et EBiSC2 travaille sur le cadre qui renforcera sa diversité, sa normalisation et sa capacité à servir la recherche universitaire et commerciale grâce à un plan d’affaires durable.

Objectif

EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank.
Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data.
To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.

Coordinateur

FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Contribution nette de l'UE
€ 2 841 583,93
Adresse
HANSASTRASSE 27C
80686 Munchen
Allemagne

Voir sur la carte

Région
Bayern Oberbayern München, Kreisfreie Stadt
Type d’activité
Research Organisations
Liens
Coût total
€ 3 432 708,93

Participants (18)